Please login to the form below

Not currently logged in
Email:
Password:

Pfizer to buy Danish consumer health firm

Pfizer has entered into an agreement to purchase the Danish firm Ferrosan's consumer healthcare business

Pfizer has entered into a definitive agreement to purchase the Danish firm Ferrosan's consumer healthcare business in a bid to strengthen its presence in the dietary supplement market.

Copenhagen-based Ferrosan specialises in dietary supplements and lifestyle products, including the multivitamin brand Multi-tabs, the probiotic Bifiform, the Omega 3 supplement Fri Flyt/Active Omega, and the oral skincare brand Imedeen.

Pfizer is buying the business from Altor 2003 Fund GP Limited, the company's principle shareholder since 2005, for an undisclosed sum in a transaction that is expected to close during the second quarter of 2011.

"The transaction will mark an important step towards expanding Ferrosan's brands through Pfizer's global footprint," Paul Sturman, president of Pfizer Consumer Healthcare, said in a statement. "As an immediate result of this acquisition, we will gain greater distribution and scale for Pfizer's well-known brands such as Centrum and Caltrate in Ferrosan's regions."

Those regions include Denmark, Russia, the Ukraine, Poland, Turkey and other countries in Central and Eastern Europe.

Pfizer acquired the multivitamin brand Centrum and the calcium supplement brand Caltrate when it bought Wyeth in a $68bn deal in 2009.

Ferrosan's medical devices business, which is focused on providing gelatin-based topical absorbable haemostatic products, will remain under Altor's ownership.

8th February 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics